Program

Overview
The preliminary time schedule with the ten scientific sessions are given in the figure below. We had a large number of excellent submissions for the free oral session on Wednesday and the Scientific Committee selected six speakers presenting „hot topics“ in neurotoxicology.

One of these speaker is Prof. Gerhard Winneke, former INA president and Hooisma Lecturer during INA-5. We are glad that Gerhard is coming back to Düsseldorf, the place where he worked for many years and promotes various areas in neurotoxicology worldwide. He was among the first researchers addressing developmental neurotoxicity in epidemiology and translating animal research to humans and vice versa.

More details about all sessions and the speakers can be found in the submenus of the program button of the menu.

 

INA-17 will start with the Jacob Hooisma lecture given by Prof. Deborah A. Cory-Slechta.

On Monday morning the David Ray Student Symposium will take place and we are encouraging all eligible candidates to apply. Details can be found here.

Currently scheduled sessions

During the call for symposia proposals already nine scientific sessions have been selected to build the backbone of INA-17. Now we also scheduled the free oral session and are happy to announce that the ENDpoiNTs project will give an overview about their current research on Novel Testing Strategies for Endocrine Disruptors linked to Developmental Neurotoxicity.

  • Immune dysregulation as a primary mechanism of early neurotoxicity – relevance to disease
  • Bridging across levels of analysis to advance neurotoxic risk determination: Toxicology for the second fifth of the 21st century
  • Next generation in vitro neurotoxicity testing: human induced pluripotent stem cell derived neuronal models
  • In vitro and other alternative methods for improving the regulatory assessment of developmental neurotoxicity
  • Integrating human and animal studies to develop mechanistically based biomarkers of neurotoxicity: A case study of occupational chlorpyrifos exposure
  • Exposure paradigms for psychoactive substances; duration and times of in vitro and in vivo neurotoxicity testing
  • Compounds’ modes-of-action (MoA) causing developmental neurotoxicity (DNT) can be used for informing adverse outcome pathways (AOPs)
  • Systems neurotoxicology: From in vivo towards predictive in vitro models
  • Use of imaging data for risk assessment: Updates, challenges and future perspectives
  • Hot Topics in Neurotoxicology (free oral session)

Details about the speakers could be found here.